Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S McCune

Showing results (171-180 of 174) with videos related to

Pageof 18
Sort By:
You have reached the last page of results.This site can display upto 174 results.
Transplantation and Cellular Therapy|April 6, 2021
Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1M Meaghan Granger, Arlene Naranjo, Rochelle Bagatell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2018
Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology GroupDouglas S Hawkins, Yueh-Yun Chi, James R Anderson, et al.
Blood|October 19, 2022
An 8-year pragmatic observation evaluation of the benefits of allogeneic HCT in older and medically infirm patients with AMLMohamed L Sorror, Ted A Gooley, Barry E Storer, et al.
Blood|August 5, 2021
Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemiaMohamed L Sorror, Barry E Storer, Amir T Fathi, et al.
Pageof 18

Showing results (171-180 of 174) with videos related to

Sort By:
Pageof 18
You have reached the last page of results.This site can display upto 174 results.
Transplantation and Cellular Therapy|April 6, 2021
Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1M Meaghan Granger, Arlene Naranjo, Rochelle Bagatell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2018
Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology GroupDouglas S Hawkins, Yueh-Yun Chi, James R Anderson, et al.
Blood|October 19, 2022
An 8-year pragmatic observation evaluation of the benefits of allogeneic HCT in older and medically infirm patients with AMLMohamed L Sorror, Ted A Gooley, Barry E Storer, et al.
Blood|August 5, 2021
Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemiaMohamed L Sorror, Barry E Storer, Amir T Fathi, et al.
Pageof 18